RWA Wealth Partners’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.76M | Buy |
36,663
+4
| +0% | +$172 | 0.02% | 285 |
|
|
2026
Q1 | $1.35M | Sell |
36,659
-51
| -0.1% | -$2.42K | 0.01% | 310 |
|
|
2025
Q4 | $1.87M | Sell |
36,710
-157,221
| -81% | -$8.04M | 0.02% | 266 |
|
|
2025
Q3 | $10.8M | Sell |
193,931
-48,129
| -20% | -$2.82M | 0.12% | 107 |
|
|
2025
Q2 | $16.7M | Buy |
242,060
+153,460
| +173% | +$10.4M | 0.21% | 74 |
|
|
2025
Q1 | $6.15M | Sell |
88,600
-2,223
| -2% | -$184K | 0.08% | 135 |
|
|
2024
Q4 | $7.81M | Buy |
90,823
+29,787
| +49% | +$3.22M | 0.1% | 115 |
|
|
2024
Q3 | $7.27M | Sell |
61,036
-22,537
| -27% | -$3.01M | 0.09% | 122 |
|
|
2024
Q2 | $11.9M | Sell |
83,573
-4,340
| -5% | -$575K | 0.16% | 84 |
|
|
2024
Q1 | $11.3M | Sell |
87,913
-4,893
| -5% | -$582K | 0.15% | 90 |
|
|
2023
Q4 | $9.6M | Buy |
92,806
+72,924
| +367% | +$7.21M | 0.14% | 93 |
|
|
2023
Q3 | $1.81M | Buy |
+19,882
| New | +$1.75M | 0.04% | 143 |
|
|
2023
Q2 | – | Sell |
-19,468
| Closed | -$1.55M | – | 348 |
|
|
2023
Q1 | $1.55M | Hold |
19,468
| – | – | 0.04% | 110 |
|
|
2022
Q4 | $1.29M | Hold |
19,468
| – | – | 0.03% | 122 |
|
|
2022
Q3 | $970K | Hold |
19,468
| – | – | 0.07% | 123 |
|
|
2022
Q2 | $1.08M | Sell |
19,468
-252
| -1% | -$14K | 0.07% | 121 |
|
|
2022
Q1 | $1.09M | Hold |
19,720
| – | – | 0.07% | 128 |
|
|
2021
Q4 | $1.1M | Sell |
19,720
-1,244
| -6% | -$67.4K | 0.07% | 130 |
|
|
2021
Q3 | $1.01M | Sell |
20,964
-1,028
| -5% | -$49.7K | 0.08% | 128 |
|
|
2021
Q2 | $921K | Sell |
21,992
-172
| -0.8% | -$6.67K | 0.07% | 137 |
|
|
2021
Q1 | $747K | Buy |
22,164
+424
| +2% | +$15.1K | 0.06% | 142 |
|
|
2020
Q4 | $759K | Buy |
21,740
+1,244
| +6% | +$43K | 0.07% | 139 |
|
|
2020
Q3 | $711K | Buy |
20,496
+28
| +0.1% | +$933 | 0.07% | 127 |
|
|
2020
Q2 | $670K | Hold |
20,468
| – | – | 0.08% | 121 |
|
|
2020
Q1 | $616K | Sell |
20,468
-1,000
| -5% | -$29.8K | 0.09% | 125 |
|
|
2019
Q4 | $621K | Buy |
21,468
+1,000
| +5% | +$27.7K | 0.06% | 151 |
|
|
2019
Q3 | $529K | Sell |
20,468
-1,000
| -5% | -$25.3K | 0.06% | 161 |
|
|
2019
Q2 | $548K | Hold |
21,468
| – | – | 0.06% | 155 |
|
|
2019
Q1 | $561K | Hold |
21,468
| – | – | 0.06% | 150 |
|
|
2018
Q4 | $494K | Sell |
21,468
-550
| -2% | -$12.2K | 0.07% | 149 |
|
|
2018
Q3 | $519K | Hold |
22,018
| – | – | 0.06% | 143 |
|
|
2018
Q2 | $508K | Hold |
22,018
| – | – | 0.06% | 155 |
|
|
2018
Q1 | $542K | Sell |
22,018
-600
| -3% | -$15.8K | 0.07% | 136 |
|
|
2017
Q4 | $607K | Buy |
22,618
+1,000
| +5% | +$25.4K | 0.07% | 153 |
|
|
2017
Q3 | $520K | Buy |
+21,618
| New | +$489K | 0.06% | 158 |
|
Other funds holding NVO
F
RWA Wealth Partners's NVO Position: Q2 2026 in Review
RWA Wealth Partners increased its Novo Nordisk (NVO) stake by 0.01% in Q2 2026, buying an estimated $172 and bringing the position to 36,663 shares worth $1.76M. The position accounts for 0.02% of the portfolio, ranked #285.
RWA Wealth Partners first reported a position in NVO in Q3 2017 and has held it in 35 quarters since. The position peaked at $16.7M in Q2 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- RWA Wealth Partners held 36,663 shares of Novo Nordisk worth $1.76M as of Q2 2026.
- RWA Wealth Partners bought 4 Novo Nordisk shares in Q2 2026, an estimated $172.
- Novo Nordisk made up 0.02% of RWA Wealth Partners's portfolio in Q2 2026, its #285 holding.
- RWA Wealth Partners first reported a position in Novo Nordisk in Q3 2017 and has held it in 35 quarters since.
- RWA Wealth Partners's Novo Nordisk position peaked at $16.7M in Q2 2025.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on RWA Wealth Partners's 13F filing for Q2 2026, filed 7 Aug 2026.